Tianyu Liu, Turner Schwartz, Apoorv P Chebolu, Jonathan C Tsui, Nirali Bhatt, Drew Scoles
{"title":"TECLISTAMAB-ASSOCIATED SCLEROUVEITIS WITH HYPOPYON.","authors":"Tianyu Liu, Turner Schwartz, Apoorv P Chebolu, Jonathan C Tsui, Nirali Bhatt, Drew Scoles","doi":"10.1097/ICB.0000000000001449","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To report a case of presumed teclistamab-associated sclerouveitis with hypopyon.</p><p><strong>Methods: </strong>Case report.</p><p><strong>Results: </strong>A 62-year-old woman with relapsed refractory multiple myeloma presented with right eye pain and decreased vision 1 week after starting teclistamab and was found to have sclerouveitis with hypopyon. She received intravitreal vancomycin and ceftazidime because of the concern for infectious endophthalmitis, but cultures were negative. Systemic workup for infectious and inflammatory etiologies was unremarkable. Her signs and symptoms improved with topical steroids and a 1-week pause in teclistamab. This case constituted a Naranjo Adverse Drug Reaction Probability Scale score of 5, representing a \"probable\" association.</p><p><strong>Conclusion: </strong>Teclistamab, a novel bispecific antibody recently approved for the treatment of relapsed or refractory multiple myeloma, may be associated with sclerouveitis with hypopyon.</p>","PeriodicalId":53580,"journal":{"name":"Retinal Cases and Brief Reports","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Retinal Cases and Brief Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/ICB.0000000000001449","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: To report a case of presumed teclistamab-associated sclerouveitis with hypopyon.
Methods: Case report.
Results: A 62-year-old woman with relapsed refractory multiple myeloma presented with right eye pain and decreased vision 1 week after starting teclistamab and was found to have sclerouveitis with hypopyon. She received intravitreal vancomycin and ceftazidime because of the concern for infectious endophthalmitis, but cultures were negative. Systemic workup for infectious and inflammatory etiologies was unremarkable. Her signs and symptoms improved with topical steroids and a 1-week pause in teclistamab. This case constituted a Naranjo Adverse Drug Reaction Probability Scale score of 5, representing a "probable" association.
Conclusion: Teclistamab, a novel bispecific antibody recently approved for the treatment of relapsed or refractory multiple myeloma, may be associated with sclerouveitis with hypopyon.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
